Insider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Sells 31,543 Shares of Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar sold 31,543 shares of the business’s stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $36.14, for a total transaction of $1,139,964.02. Following the transaction, the chief executive officer now owns 211,718 shares of the company’s stock, valued at approximately $7,651,488.52. This represents a 12.97 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Neil Kumar also recently made the following trade(s):

• On Tuesday, January 28th, Neil Kumar sold 326,932 shares of BridgeBio Pharma stock. The stock was sold at an average price of $36.29, for a total transaction of $11,864,362.28.

BridgeBio Pharma Trading Up 2.3 %

Shares of BBIO stock opened at $36.29 on Thursday. The firm’s fifty day moving average price is $31.53 and its two-hundred day moving average price is $27.79. BridgeBio Pharma, Inc. has a 1 year low of $21.62 and a 1 year high of $37.81. The firm has a market capitalization of $6.86 billion, a P/E ratio of -15.06 and a beta of 1.07.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Evercore ISI raised their price objective on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research note on Monday, December 23rd. Bank of America lifted their price objective on BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a report on Monday, November 25th. Scotiabank raised their target price on shares of BridgeBio Pharma from $48.00 to $49.00 and gave the stock a “sector outperform” rating in a report on Wednesday, February 12th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $49.00 price target on shares of BridgeBio Pharma in a research note on Thursday, February 13th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $49.08.

Institutional Trading of BridgeBio Pharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in BridgeBio Pharma by 6.2% during the fourth quarter. Vanguard Group Inc. now owns 15,077,915 shares of the company’s stock valued at $413,738,000 after purchasing an additional 879,059 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of BridgeBio Pharma by 1.9% during the 4th quarter. Janus Henderson Group PLC now owns 4,907,533 shares of the company’s stock worth $134,672,000 after purchasing an additional 89,521 shares in the last quarter. Farallon Capital Management LLC raised its stake in shares of BridgeBio Pharma by 140.1% during the 4th quarter. Farallon Capital Management LLC now owns 4,195,000 shares of the company’s stock worth $115,111,000 after purchasing an additional 2,448,000 shares in the last quarter. Frazier Life Sciences Management L.P. boosted its holdings in shares of BridgeBio Pharma by 1.1% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,800,457 shares of the company’s stock valued at $104,285,000 after buying an additional 40,000 shares during the last quarter. Finally, Capital Research Global Investors grew its stake in shares of BridgeBio Pharma by 34.9% in the fourth quarter. Capital Research Global Investors now owns 3,526,747 shares of the company’s stock valued at $96,774,000 after buying an additional 912,439 shares in the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.